GlassScriptPhysician profile
Andrew Hiran Dep
NPI 1093276255
$789.78
in general payments reported to CMS, 2019-2025
18 companies · $53.13 in 2025
The $53.13 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.90 · 2022: $166 · 2023: $199 · 2024: $311 · 2025: $53.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.81 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $212.91 | 2022-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $103.47 | 2021-2024 | Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.49 | 2023-2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $47.29 | 2022-2024 | |
| Pfizer INC. | $43.62 | 2021-2023 | |
| Astellas Pharma US INC | $41.85 | 2022 | |
| Genzyme Corporation | $32.47 | 2023-2024 | |
| Pulmonx Corporation | $31.70 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Janssen Pharmaceuticals, INC | $23.97 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.75 | 2022 | |
| United Therapeutics Corporation | $21.95 | 2022 | |
| Merck Sharp & Dohme LLC | $20.01 | 2024 | Winrevair |
| Abiomed | $19.77 | 2024 | Impella |
| Sandoz INC. | $19.74 | 2023 | Treprostinil |
| Xeris Pharmaceuticals, INC. | $19.15 | 2023 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $18.95 | 2023 | Fetroja |
| Regeneron Healthcare Solutions, INC. | $18.47 | 2024 | Dupixent |
| Philips North America LLC | $16.22 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.